Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study.


Autoria(s): Mekahli D.; Liutkus A.; Ranchin B.; Yu A.; Bessenay L.; Girardin E.; Van Damme-Lombaerts R.; Palcoux J.B.; Cachat F.; Lavocat M.P.; Bourdat-Michel G.; Nobili F.; Cochat P.
Data(s)

2009

Resumo

Long-term outcome of idiopathic steroid-resistant nephrotic syndrome was retrospectively studied in 78 children in eight centers for the past 20 years. Median age at onset was 4.4 years (1.1-15.0 years) and the gender ratio was 1.4. Median follow-up period was 7.7 years (1.0-19.7 years). The disease in 45 patients (58%) was initially not steroid-responsive and in 33 (42%) it was later non-responsive. The main therapeutic strategies included administration of ciclosporine (CsA) alone (n = 29; 37%) and CsA + mycophenolate mofetil (n = 18; 23%). Actuarial patient survival rate after 15 years was 97%. Renal survival rate after 5 years, 10 years and 15 years was 75%, 58% and 53%, respectively. An age at onset of nephrotic syndrome (NS) > 10 years was the only independent predictor of end-stage renal disease (ESRD) in a multivariate analysis using a Cox regression model (P < 0.001). Twenty patients (26%) received transplants; ten showed recurrence of the NS: seven within 2 days, one within 2 weeks, and two within 3-5 months. Seven patients lost their grafts, four from recurrence. Owing to better management, kidney survival in idiopathic steroid-resistant nephrotic syndrome (SRNS) has improved during the past 20 years. Further prospective controlled trials will delineate the potential benefit of new immunosuppressive treatment.

Identificador

http://serval.unil.ch/?id=serval:BIB_E788BE200669

isbn:1432-198X[electronic]

pmid:19280229

doi:10.1007/s00467-009-1138-5

isiid:000267109300012

Idioma(s)

en

Fonte

Pediatric Nephrology, vol. 24, no. 8, pp. 1525-1532

Palavras-Chave #Adolescent; Child; Child, Preschool; Cyclophosphamide/therapeutic use; Cyclosporine/therapeutic use; Drug Resistance; Female; Humans; Immunosuppressive Agents/therapeutic use; Infant; Male; Mycophenolic Acid/analogs & derivatives; Mycophenolic Acid/therapeutic use; Nephrotic Syndrome/drug therapy; Retrospective Studies; Steroids/therapeutic use; Time Factors; Treatment Outcome
Tipo

info:eu-repo/semantics/article

article